Tacke F, Horn P, Wai-Sun Wong V, Ratziu V, Bugianesi E, Francque S, et al. EASL–EASD–EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81:492–542. https://doi.org/10.1016/j.jhep.2024.04.031.

Article  CAS  Google Scholar 

Targher G, Valenti L, Byrne CD. Metabolic dysfunction–Associated steatotic liver disease. N Engl J Med. 2025;393:683–98. https://doi.org/10.1056/NEJMra2412865.

Article  CAS  PubMed  Google Scholar 

Cusi K, Abdelmalek MF, Apovian CM, Balapattabi K, Bannuru RR, Barb D, et al. Metabolic dysfunction–associated steatotic liver disease (MASLD) in people with diabetes: the need for screening and early intervention. A consensus report of the American Diabetes Association. Diabetes Care. 2025;48:1057–82. https://doi.org/10.2337/dci24-0094.

Article  CAS  PubMed  Google Scholar 

Mollace R, Longo S, Nardin M, Tavernese A, Musolino V, Cardamone A, et al. Role of MASLD in CVD: a review of emerging treatment options. Diabetes Res Clin Pract. 2024;217:111891. https://doi.org/10.1016/j.diabres.2024.111891.

Article  CAS  PubMed  Google Scholar 

Longo S, Rizza S, Federici M. Microbiota-gut-brain axis: relationships among the vagus nerve, gut microbiota, obesity, and diabetes. Acta Diabetol. 2023;60:1007–17. https://doi.org/10.1007/s00592-023-02088-x.

Article  PubMed  PubMed Central  Google Scholar 

Raverdy V, Tavaglione F, Chatelain E, Lassailly G, De Vincentis A, Vespasiani-Gentilucci U, et al. Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease. Nat Med. 2024;30:3624–33. https://doi.org/10.1038/s41591-024-03283-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Steinberg GR, Valvano CM, De Nardo W, Watt MJ. Integrative metabolism in MASLD and MASH: pathophysiology and emerging mechanisms. J Hepatol. 2025;83:584–95. https://doi.org/10.1016/j.jhep.2025.02.033.

Article  CAS  PubMed  Google Scholar 

Newsome PN, Ambery P. Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver. J Hepatol. 2023;79:1557–65. https://doi.org/10.1016/j.jhep.2023.07.033.

Article  CAS  PubMed  Google Scholar 

Hasan N, Yang H. Factors affecting the composition of the gut microbiota, and its modulation. PeerJ. 2019;7:e7502. https://doi.org/10.7717/peerj.7502.

Article  PubMed  PubMed Central  Google Scholar 

Kelly CJ, Zheng L, Campbell EL, Saeedi B, Scholz CC, Bayless AJ, et al. Crosstalk between microbiota-derived short-chain fatty acids and intestinal epithelial HIF augments tissue barrier function. Cell Host Microbe. 2015;17:662–71. https://doi.org/10.1016/j.chom.2015.03.005.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sekirov I, Russell SL, Antunes LCM, Finlay BB. Gut microbiota in health and disease. Physiol Rev. 2010;90:859–904. https://doi.org/10.1152/physrev.00045.2009.

Article  CAS  PubMed  Google Scholar 

Pabst O, Hornef MW, Schaap FG, Cerovic V, Clavel T, Bruns T. Gut–liver axis: barriers and functional circuits. Nat Rev Gastroenterol Hepatol. 2023;20:447–61. https://doi.org/10.1038/s41575-023-00771-6.

Article  PubMed  Google Scholar 

Ni Y, Ni L, Zhuge F, Fu Z. The gut microbiota and its metabolites, novel targets for treating and preventing non‐alcoholic fatty liver disease. Mol Nutr Food Res. 2020;64:2000375. https://doi.org/10.1002/mnfr.202000375.

Article  CAS  Google Scholar 

Han H, Yi B, Zhong R, Wang M, Zhang S, Ma J, et al. From gut microbiota to host appetite: gut microbiota-derived metabolites as key regulators. Microbiome. 2021;9:162. https://doi.org/10.1186/s40168-021-01093-y.

Article  PubMed  PubMed Central  Google Scholar 

Jasirwan COM, Muradi A, Hasan I, Simadibrata M, Rinaldi I. Correlation of gut Firmicutes/Bacteroidetes ratio with fibrosis and steatosis stratified by body mass index in patients with non-alcoholic fatty liver disease. Biosci Microbiota, Food and Health. 2021;40:50–8. https://doi.org/10.12938/bmfh.2020-046.

Article  CAS  Google Scholar 

Loomba R, Seguritan V, Li W, Long T, Klitgord N, Bhatt A, et al. Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. Cell Metab. 2019;30:607. https://doi.org/10.1016/j.cmet.2019.08.002.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Astbury S, Atallah E, Vijay A, Aithal GP, Grove JI, Valdes AM. Lower gut microbiome diversity and higher abundance of proinflammatory genus Collinsella are associated with biopsy-proven nonalcoholic steatohepatitis. Gut Microbes. 2020;11:569–80. https://doi.org/10.1080/19490976.2019.1681861.

Article  CAS  PubMed  Google Scholar 

Pirola CJ, Landa MS, Schuman M, García SI, Salatino A, Sookoian S. Metabolic dysfunction-associated steatotic liver disease exhibits sex-specific microbial heterogeneity within intestinal compartments. Clin Mol Hepatol. 2025;31:179–95. https://doi.org/10.3350/cmh.2024.0359.

Article  PubMed  Google Scholar 

Ballestri S, Nascimbeni F, Baldelli E, Marrazzo A, Romagnoli D, Lonardo A. NAFLD as a sexual dimorphic disease: role of gender and reproductive status in the development and progression of nonalcoholic fatty liver disease and inherent cardiovascular risk. Adv Ther. 2017;34(6):1291–326. https://doi.org/10.1007/s12325-017-0556-1.

Article  PubMed  PubMed Central  Google Scholar 

Mouries J, Brescia P, Silvestri A, Spadoni I, Sorribas M, Wiest R, et al. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development. J Hepatol. 2019;71:1216–28. https://doi.org/10.1016/j.jhep.2019.08.005.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Leigh S-J, Morris MJ. Diet, inflammation and the gut microbiome: Mechanisms for obesity-associated cognitive impairment. Biochimica et Biophysica Acta (BBA) - Mol Basis Dis. 2020;1866:165767. https://doi.org/10.1016/j.bbadis.2020.165767.

Article  CAS  Google Scholar 

Tomita K. Tumour necrosis factor signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut. 2006;55:415–24. https://doi.org/10.1136/gut.2005.071118.

Article  CAS  PubMed  Google Scholar 

Shao L, Song Y, Shi JP. [Role of gut-liver-immune axis in the pathogenesis of nonalcoholic steatohepatitis]. Zhonghua Gan Zang Bing Za Zhi. 2021;29:505–9. https://doi.org/10.3760/cma.j.cn501113-20210430-00215.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tsukamoto H, Takeuchi S, Kubota K, Kobayashi Y, Kozakai S, Ukai I, et al. Lipopolysaccharide (LPS)-binding protein stimulates CD14-dependent Toll-like receptor 4 internalization and LPS-induced TBK1–IKKϵ–IRF3 axis activation. J Biol Chem. 2018;293:10186–201. https://doi.org/10.1074/jbc.M117.796631.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24:908–22. https://doi.org/10.1038/s41591-018-0104-9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Csak T, Velayudham A, Hritz I, Petrasek J, Levin I, Lippai D, et al. Deficiency in myeloid differentiation factor-2 and toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis in mice. Am J Physiol-Gastrointest Liver Physiol. 2011;300:G433–41. https://doi.org/10.1152/ajpgi.00163.2009.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lastra G, Manrique C. Perivascular adipose tissue, inflammation and insulin resistance: link to vascular dysfunction and cardiovascular disease. Horm Mol Biol Clin Investig. 2015;22:19–26. https://doi.org/10.1515/hmbci-2015-0010.

Article  CAS